introduction Metastatic disease to the brain is a common cause of death from melanoma and carries a poor prognosis in melanoma patients with a median overall survival (OS) of 4-5 months reported in the literature [1] [2] [3] . Standard management options for melanoma brain metastases (BMs) include surgery, stereotactic radiation, whole-brain radiation therapy (WBRT), or combination treatment. Local BM control rates for melanoma following stereotactic radiation alone are as high as 80% [4, 5] .
There have been major recent advances in targeted therapies in the management of metastatic melanoma including BRAF and MEK inhibitors as well as immune checkpoint blockade agents such as anti-CTLA-4 and anti-programmed death-1 (anti-PD-1) antibodies. In particular, targeting the programmed death-1 (PD-1) pathway in metastatic melanoma patients has demonstrated substantial clinical benefit. Following chronic T-cell activation, the inhibitory receptor PD-1 is induced on T cells, which engages with one of its ligands, PD-L1, found on tissue-based macrophages, antigen-presenting cells, and tumor cells to mediate immune escape via T-cell exhaustion [6] . The anti-PD-1 agents nivolumab and pembrolizumab target this pathway by blocking the PD-1/PD-L1 interaction, thereby preventing T-cell exhaustion and immune evasion. Clinical trials with anti-PD-1 therapies in patients with metastatic melanoma have demonstrated objective responses in 25%-45% of patients, many of which can be durable [7] [8] [9] [10] . However, there are currently limited data on the use of anti-PD-1 therapies in patients with melanoma BMs and when used in conjunction with radiation.
Several retrospective studies have assessed the use of BRAF inhibitors or anti-CTLA-4 therapy (ipilimumab) with stereotactic radiosurgery (SRS) in the management of melanoma BMs. Initial case reports with the use of the BRAF inhibitor vemurafenib and radiation ( palliative radiation to bone, WBRT) have suggested increased severity of skin reactions (focal dermatitis) with combined treatment [11] [12] [13] . Larger retrospective studies with BRAF inhibitors and SRS or WBRT have failed to demonstrate clearly increased cutaneous toxicity or increased frequency of edema and hemorrhage of treated BMs [14] [15] [16] . Similarly, the use of ipilimumab in patients undergoing SRS or WBRT has demonstrated little new toxicity above the expected changes that can occur with radiation to the brain alone [17] [18] [19] [20] . Interestingly, these studies have suggested the possibility of improved local BM control and OS compared with standard current treatment when utilized in patients with melanoma BMs requiring radiation therapy [17] [18] [19] [20] . The purpose of this study is to assess the toxicities and outcomes in patients treated with stereotactic radiation and anti-PD-1 therapy for melanoma BMs.
materials and methods
Data were analyzed retrospectively from two nivolumab protocols enrolling 160 patients with resected or unresectable metastatic melanoma at Moffitt Cancer Center. The protocol for unresectable disease, NCT01176461, was a phase I study of nivolumab with or without a multipeptide vaccine (MART-1, NY-ESO, gp100 peptides emulsified in Montanide ISA 51VG) in patients with unresectable stage III or IV melanoma) including 16 patients with BMs [21] . The protocol in the resected (adjuvant) setting, NCT01176474, was a phase I study of nivolumab plus the same multipeptide vaccine in patients with resected stage IIIC or IV melanoma, which included 10 patients with resected BMs [22] . Patients were included if they were diagnosed with BMs that were treated with stereotactic radiation within 6 months of receiving nivolumab (either before, during, or after nivolumab administration). Patients underwent SRS or fractionated stereotactic radiotherapy (FSRT) between December 2010 and July 2014 and were followed until February 2015. The study was approved by the University of South Florida Institutional Review Board.
stereotactic radiation technique
BMs were assessed using magnetic resonance imaging (MRI) (Siemens Sonata, Siemens Medical Systems, Erlangen, Germany) with 1 mm slices for treatment planning purposes before the delivery of radiation. The MRI image was co-registered and fused with computed tomography (CT) simulation imaging (General Electric Medical System, Milwaukee, WI). Patient immobilization was achieved by using a commercially available head mask fixation system (BrainlabAG, Feldkirchen, Germany). A uniform 1 mm expansion of the gross tumor volume was used to create the planning target volume (PTV). All BMs were treated with SRS in a single session except 12 BMs treated with FSRT of which 9 were in the postoperative setting. Doses were prescribed to ensure coverage of at least 95% of the PTV with the prescription dose. Treatments were delivered using multiple dynamic conformal arcs or intensity-modulated radiotherapy. Treatments were delivered with the BrainLab Novalis Classic linear accelerator (LINAC) with 6 MV photons. Image guidance was provided with the BrainLab ExacTrac positioning system.
follow-up
Patients in this study were followed with examinations by the treating radiation oncologist, neurosurgeon, and/or medical oncologist with MRI imaging at 2-to 3-month intervals. At each visit, neurologic status was assessed. Local BM failure was defined as at least a 20% radiographic increase in the size of the previously irradiated area in accordance with RECIST criteria [23] that remained consistent or continued to increase on subsequent imaging whereas local BM control included all treated lesions not meeting this definition. The distinction between local failure and radiation treatment changes or pseudoprogression was made alongside a neuro-radiologist. Pseudoprogression or radiation treatment changes were defined as volumetric changes on follow-up MRI scans 0-3 months post-radiation treatment, which resolved on serial T 1 -weighted MRI imaging. Distant BM failure was defined as new BM or leptomeningeal enhancement outside the previously irradiated field. Distant BM control was defined as freedom from the development of BM or leptomeningeal disease outside of the irradiated field. The primary end point of this study was neurotoxicity during or after SRS/FSRT assessed by history, physical examination, and corticosteroid requirement. In addition, semiquantification of edema with a scale of 0 (low) to 3 (high) and hemorrhage of BMs demonstrating local failure (i.e. ≥20% increase in diameter) on follow-up MRI was performed; a similar scale has been previously utilized in this setting [14] . Secondary end points in this study included local and distant BM control as well as OS.
statistical analysis
Statistical analyses were carried out using JMP 11 (SAS Institute, Inc., Cary, NC). Descriptive statistics were used to summarize the cohort including median and range for continuous variables or counts and percentages for categorical variables. The local and distant BM control rates, as well as OS were calculated from the date of BM diagnosis or radiation treatment to the date of progression or death using the Kaplan-Meier method, with the log-rank test used to test differences between groups. Cox proportional hazard model analyses were carried out. A two-tailed P < 0.05 was considered statistically significant.
results

patient and lesion characteristics
Twenty-six patients with a total of 73 BMs treated over 30 sessions were identified. There were four patients treated in two sessions. Patient characteristics are summarized in Table 1 . The median age of patients was 54.5 years (range: 33-79 years) and the majority of patients were male (n = 17; 65%). Nineteen patients were treated on protocol NCT01176461 for unresectable disease, n = 10 with vaccine and n = 9 without vaccine. Additionally, seven patients were treated on NCT01176474 in the resected (adjuvant) setting, all with vaccine. Nine patients were treated with cytotoxic chemotherapy before starting nivolumab (six carboplatin/paclitaxel, one cisplatin, one dacarbazine and bevacizumab, and one temozolomide). In addition, 17 patients received prior immunotherapies (4 interleukin-2 and 13 ipilimumab) and 4 patients received prior targeted agents (2 BRAF inhibitor and 2 BRAF and MEK inhibitors). The majority of patients were diagnosis-specific-graded prognostic assessment (DS-GPA) class 3-4 (n = 19; 73%) whereas 7 patients (23%) were class 1-2. Seven patients (27%) were treated for a single site of metastasis while 19 patients (73%) received treatment for multiple sites of metastases (range: 2-10). The median number of lesions treated during each radiation session was 2 (range: 1-8).
Lesion characteristics are summarized in Table 2 . The median follow-up after radiation for all lesions was 9.4 months (range: 1.2-41.5 months) with a median follow-up of 15.1 months (range: 4.3-42 months) following BM diagnosis. Five lesions (7%) in three patients were treated with radiation during nivolumab treatment (diagnosed during participation on trial and allowed to continue with nivolumab therapy after radiation). In these lesions, the number of days between the administration of nivolumab and radiation was 7 days (range: 6-10 days) and the number of days from radiation to the administration of the next nivolumab dose was 6 days (range: 6-21 days). A total of 35 lesions (48%) were treated with radiation after receiving nivolumab (median 1 month; range: 0.4-4.5 months), and 33 lesions (45%) were treated with radiation before receiving nivolumab (median 3 months; range: 1-6 months). All of these BMs were treated with SRS, except for 12 lesions (16%) treated with FSRT. The most common SRS doses were 21 Gy (n = 26; 36%) and 24 Gy (n = 25; 34%).
neurotoxicity
Three patients were placed on prophylactic steroids during radiation. An additional patient was initiated on steroids for grade 2 headaches (moderate pain; limiting instrumental activities of daily living) following SRS, which provided symptomatic relief. This patient received nivolumab 3 months before SRS. No other treatment-related neurologic toxicities (such as nausea, vision local BM control, edema, and hemorrhage
Eight lesions were found to undergo local failure; a ≥20% increase in volume confirmed on subsequent imaging in 7 patients, all of which had been treated with SRS. Kaplan-Meier local BM control rates at 6 and 12 months were 91% and 85%, respectively ( Figure 1A ). For lesions undergoing SRS (excluding those treated with FSRT), local BM control rates at 6 and 12 months were 89% and 82%, respectively. Local BM failure occurred at a median of 6 months post-treatment (range: 4.5-8.0 months). Two local BM failures were treated during anti-PD-1 therapy, one was treated before, and five after anti-PD-1 inhibition. There were no statistically significant associations between clinical and treatment variables and local BM failure. For lesions demonstrating local failure, hemorrhage was evaluated alongside a semiquantitative scale for edema graded on a scale of 0-3. Hemorrhage was noted in 4 lesions and edema was noted in 7 lesions. In those lesions with hemorrhage, this was observed at a median of 7.7 months (range: Table 3 .
distant BM control
Thirteen patients developed distant BM failure within the CNS. Distant BM failure was noted at a median of 4.6 months (range: 2.6-29.1 months) following treatment with SRS/FSRT. Rates of 6-and 12-month distant BM control for all treatment sessions were 66% and 53%, respectively, as seen in Figure 1B . Of the patients in both trials who experienced distant BM failure, 4 received WBRT and 6 patients received additional SRS to new sites of metastases.
overall survival
Sixteen patients (62%) had died at the time of study analysis. Median OS for patients enrolled on protocol NCT01176461 (unresected disease) was 11.8 months (range: 0.5-33.9 months) from the date of radiation treatment (Figure 2 ), 12.2 months (range: 0.5-41.6 months) from the date of first BM diagnosis, and 12.0 months (range: 3.0-30.2 months) from date of nivolumab treatment initiation. Six-and 12-month OS rates were 78% and 55% in patients with unresected disease (from the date of radiation treatment; Figure 2 ). The median OS for patients treated on protocol NCT01176474 (resected disease) was not reached (Figure 2 ). Six-and 12-month OS rates were both 100% in this group.
A KPS of 70 compared with >70 was found to be predictive of OS on univariate analysis (hazard ratio 4.09; 95% confidence interval 1.16-13.8, P = 0.03) for patients enrolled on NCT01176461 (Table 4 ). Other variables, including a number of BMs, age, DS-GPA, and timing of anti-PD-1 therapy with radiation were not significant. Due to small sample size, univariate analysis was not conducted on the cohort of patients from NCT01176474.
discussion
In this analysis of stereotactic radiation treatment administered either before, during or after anti-PD-1 therapy, we noted several findings: (i) stereotactic radiation to melanoma BMs was well tolerated in patients treated with nivolumab, (ii) compared with historical data, local BM control was similar whereas distant BM control appears improved, and (iii) OS of melanoma Figure 2 . OS of patients from the date of stereotactic radiation enrolled on protocols NCT01176461 (n = 19; unresected disease) and NCT01176474 (n = 7; resected disease). Median OS of patients enrolled on NCT01176461 was 11.8 months (range: 0.5-33.9 months) and not reached for patients enrolled on NCT01176474. The use of localized stereotactic radiation in lieu of WBRT has become quite common in the management of four or fewer melanoma BMs [24] . Utilizing either a linear accelerator or Gamma Knife technique, focal radiation is delivered thereby decreasing the risk of neurocognitive sequelae seen with WBRT [25, 26] . SRS alone is well tolerated with a 4% incidence of late neurologic toxicity [27] ; radiation necrosis rates have been reported to be 8% and 11% at 12 and 24 months, respectively, following SRS using surgical pathology [24] . Using radiographic criteria, symptomatic radionecrosis has been reported to be 10% and asymptomatic in 14% of lesions following SRS [28] . Preclinical data have shown a radiosensitization effect with vemurafenib [29] . While the combined use of radiation and vemurafenib might improve disease control, several reports have suggested off-target effects may occur. Radiation recall dermatitis has been reported in a previously irradiated area as well as scalp reactions in patients treated with WBRT [11] [12] [13] 30] . However, larger series such as the one from our group with 24 patients and from Gaudy-Marqueste et al. with 30 patients have not demonstrated increased skin toxicity with the combined treatment of BRAF inhibitors with SRS and/or WBRT [14] [15] [16] . Neurotoxicity, including edema and hemorrhage of treated BM lesions, also appears to be rare in this setting. The use of SRS delivered either before or during administration of a BRAF inhibitor for melanoma BMs resulted in a >20% increase in size in 13% of tumors, with <3% showing hemorrhage and 1% showing edema [14] .
While there are no published reports to date on the safety of WBRT/SRS and anti-PD-1 therapy for BM patients, several retrospective studies have previously analyzed the immune checkpoint inhibitor ipilimumab in this setting. In the largest report by Kiess et al., 46 melanoma BM patients who received SRS and ipilimumab were identified, including 15 patients where the treatment was concurrent [18] . Half of the cases where SRS was performed before or during ipilimumab showed >150% increase in tumor size (majority of cases were described as postradiation changes, not tumor progression, according to the authors). This increase in tumor size occurred in only 13% of patients where SRS was performed after ipilimumab. Intratumoral hemorrhage and/or edema were seen in 82% of patients. In particular, 40% of patients receiving concurrent treatment had intratumoral hemorrhage and some experienced neurologic events such as headaches, seizures, and cognitive changes. In another study of 58 melanoma BM patients treated with SRS, including 25 patients who also received ipilimumab, there was no difference in intratumoral hemorrhage rates between the groups [17] . Similarly, two other studies showed that intracranial hemorrhage and edema after SRS or WBRT and ipilimumab were relatively uncommon and not clearly worse compared with radiation alone [19, 20] .
In our series of 26 patients treated with stereotactic radiation and nivolumab, local failure was seen in 7 patients (27% of patients; 11% of lesions). In these patients, intratumoral hemorrhage occurred in only three subjects and edema was noted in six subjects. The BM local failure rate was similar to that reported by Gaudy-Marqueste et al. with vemurafenib plus SRS [14] , whereas the rates of intratumoral hemorrhage (5%) and edema (10%) were slightly higher. However, the extent of edema (range: grade 0-3), appeared less in our current study where only two treated tumors were grade 3 (severe edema), when compared with three immediate cases and four late cases of severe edema in the vemurafenib study. Additionally, no difference in toxicity or other clinical end points was noted in patients that did or did not receive the multi-peptide vaccine in this study. The median follow-up of 9.4 months for the current study is longer than the 4.7-month median follow-up time in the study by GaudyMarqueste et al.; however, it still may not be long enough to capture all cases of radionecrosis. In addition, the median size of lesions treated in our study was relatively small with a PTV of 0.51 cm 3 , which would be expected to result in lower rates of radionecrosis. Overall, the event rates were similar to that reported for SRS alone and the small disparities may be accounted for by small sample sizes and differences in radiologic interpretation.
Where there seems to be a more pronounced difference in comparison with the ipilimumab plus SRS data published by Kiess et al., which showed 50% of treated patients had BMs increased by >150%, frequently with evidence of edema/hemorrhage [18] . Similarly, more cases of neurologic adverse events were reported in that study compared with ours where we found only one patient with grade 2 headaches. This suggests there may be a biologic difference in the postradiation changes occurring in BMs from patients receiving an anti-CTLA-4 therapy as opposed to an anti-PD-1 therapy. No long-term neurologic toxicities were identified in our series; however, median followup from radiation was 9.4 months and 3 patients had ongoing grade 3 vasogenic edema at last follow-up. A prospective study comparing the two immunotherapies in melanoma BM patients treated with SRS would be required to confirm this observation.
The potential clinical benefit of stereotactic radiation and anti-PD-1 therapy was addressed by three parameters in our study: local BM control within the radiated lesion(s), distant BM control, and OS. With regard to local and distant BM control following SRS alone in the management of melanoma BMs, 12-month rates have ranged between 56%-80% and 25%-33%, respectively [4, [31] [32] [33] . Similarly, reports with the use of SRS combined with BRAF inhibitors have shown 12-month local and distant BM control rates of approximately 60%-75% and 23%, respectively [15] . When SRS is combined with ipilimumab, the 12-month local BM control rate was >80% whereas the distant BM control rate was 8%-36% depending on the timing of ipilimumab (worse in patients receiving SRS after ipilimumab) [18] . In our nivolumab study, a comparable 12-month local BM control rate was observed (85%), but there was a better distant BM control rate (53%). This may be due to the higher clinical activity seen with nivolumab compared with ipilimumab in metastatic melanoma patients. Interestingly, a recent report showed that more than half of melanoma BMs stain positive for PD-L1 by immunohistochemistry accompanied by lymphocytic infiltrates, which supports the potential for anti-PD-1 therapies in melanoma BM patients [34] .
Historically, survival for metastatic melanoma patients with BMs has been lower than those without BMs. Even in select patients managed with surgery or SRS, the median OS of patients with melanoma BMs has ranged from 8 to 10 months [5] . Now with the availability of more active systemic therapies, including BRAF and immune checkpoint inhibitors, survival of patients has significantly improved [9, 12, [35] [36] [37] . In particular, the responses to immunotherapy appear prolonged with long-term survival in 20% of patients treated with ipilimumab and perhaps 30% of patients treated with nivolumab [7, 38] . While ipilimumab does have some melanoma BM activity (5%-16% objective response rate), median OS of only 3.7-7 months has been reported [39] . Retrospective studies have shown that a combined approach wherein ipilimumab and SRS were utilized to manage melanoma BM patients may improve median OS, ranging from 12.4 up to 21.3 months [18] [19] [20] . In the current study of stereotactic radiation and nivolumab, we demonstrated a median OS of 12 months from the date of nivolumab initiation and 11.8 months from the date of stereotactic radiation in patients with unresected disease (NCT01176461). This can be compared with the long-term follow-up data from the phase I study of nivolumab (only 3% of melanoma patients had a history of BMs) where the median OS was 16.8 months [7] . There are several limitations to the present study. We performed a retrospective assessment on a subgroup of patients with BMs treated with radiation to assess neurologic and BM control outcomes, which were not pre-specified end points of either study. Second, although the present analysis was undertaken alongside a neuro-radiologist to assess local control outcomes, in those patients that experienced a local failure, surgical pathology was not available to definitively distinguish local failure from radionecrosis. Lastly, the sample size with three different nivolumab doses may impact how these results can be applied to generalized patient populations (although the majority of the metastatic patients had 3 mg/kg, the standard FDA approved dose). However, these data suggest that rates of neurotoxicities are low when nivolumab is administered to melanoma patients before, during, or after stereotactic radiation for BM management. Similarly, distant BM control and OS may be improved with nivolumab in this patient population over historical data. These results warrant further prospective evaluation to assess the potential synergistic effect that may occur with anti-PD-1 inhibition and stereotactic radiation for metastatic melanoma to the brain. acknowledgements
